Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.

Chappell JC, Turner PK, Pak YA, Bacon J, Chiang AY, Royalty J, Hall SD, Kulanthaivel P, Bonventre JV.

Clin Pharmacol Ther. 2019 May;105(5):1187-1195. doi: 10.1002/cpt.1296. Epub 2018 Dec 30.

PMID:
30449032
2.

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.

Invest New Drugs. 2018 Aug;36(4):629-637. doi: 10.1007/s10637-017-0532-2. Epub 2017 Dec 1.

3.

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.

Tate SC, Sykes AK, Kulanthaivel P, Chan EM, Turner PK, Cronier DM.

Clin Pharmacokinet. 2018 Mar;57(3):335-344. doi: 10.1007/s40262-017-0559-8.

4.

Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs.

Lucas AT, Herity LB, Kornblum ZA, Madden AJ, Gabizon A, Kabanov AV, Ajamie RT, Bender DM, Kulanthaivel P, Sanchez-Felix MV, Havel HA, Zamboni WC.

Int J Pharm. 2017 Jun 30;526(1-2):443-454. doi: 10.1016/j.ijpharm.2017.04.079. Epub 2017 May 2.

PMID:
28473237
5.

Comparison between Radioanalysis and 19F Nuclear Magnetic Resonance Spectroscopy in the Determination of Mass Balance, Metabolism, and Distribution of Pefloxacin.

Hu H, Katyayan KK, Czeskis BA, Perkins EJ, Kulanthaivel P.

Drug Metab Dispos. 2017 Apr;45(4):399-408. doi: 10.1124/dmd.116.073809. Epub 2017 Feb 10.

PMID:
28188298
6.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

7.

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Tate SC, Burke TF, Hartman D, Kulanthaivel P, Beckmann RP, Cronier DM.

Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.

8.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

9.

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.

Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, Gelbert LM, Shannon HE, Sanchez-Martinez C, De Dios A.

Drug Metab Dispos. 2015 Sep;43(9):1360-71. doi: 10.1124/dmd.114.062745. Epub 2015 Jul 6.

PMID:
26149830
10.

Utilizing 19F NMR to investigate drug disposition early in drug discovery.

Hu H, Huang N, Yi P, Hui YH, Dally RD, Ehlhardt WJ, Kulanthaivel P.

Xenobiotica. 2015;45(12):1081-91. doi: 10.3109/00498254.2015.1040866. Epub 2015 May 6.

PMID:
25946562
11.

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD.

Clin Pharmacol Ther. 2015 Jul;98(1):76-86. doi: 10.1002/cpt.128. Epub 2015 May 19. Review.

PMID:
25808023
12.

Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.

Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC.

Drug Metab Dispos. 2013 Apr;41(4):714-26. doi: 10.1124/dmd.112.048488. Epub 2013 Jan 10.

PMID:
23305709
13.

Metabolism of LY654322, a growth hormone secretagogue, to an unusual diimidazopyridine metabolite.

Borel AG, Jones TM, Barbuch RJ, Jackson DA, Kulanthaivel P, Mattiuz E, Klimkowski VJ, Wheeler WJ, Rener GA.

Drug Metab Dispos. 2011 May;39(5):740-9. doi: 10.1124/dmd.110.037598. Epub 2011 Feb 23.

PMID:
21346003
14.

Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.

Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, Barbuch RJ, Chaudhary A, Ayan-Oshodi MA, Ring BJ.

Drug Metab Dispos. 2010 Apr;38(4):554-65. doi: 10.1124/dmd.109.030841. Epub 2010 Jan 14.

PMID:
20075192
15.

A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds.

Sawayama AM, Chen MM, Kulanthaivel P, Kuo MS, Hemmerle H, Arnold FH.

Chemistry. 2009 Nov 2;15(43):11723-9. doi: 10.1002/chem.200900643.

16.

Simultaneous characterization of a mixture of fluorochemicals using three-dimensional 19F-1H heteronuclear TOCSY filtered/edited NMR experiments.

Hu H, Kulanthaivel P, Krishnamurthy K.

J Org Chem. 2007 Aug 3;72(16):6259-62. Epub 2007 Jun 30.

PMID:
17604400
17.

Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.

Sun H, Ehlhardt WJ, Kulanthaivel P, Lanza DL, Reilly CA, Yost GS.

J Pharmacol Exp Ther. 2007 Aug;322(2):843-51. Epub 2007 May 14.

PMID:
17502430
18.

Selective metabolism of vincristine in vitro by CYP3A5.

Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD.

Drug Metab Dispos. 2006 Aug;34(8):1317-27. Epub 2006 May 5.

PMID:
16679390
19.
20.

In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.

Barbuch RJ, Campanale K, Hadden CE, Zmijewski M, Yi P, O'Bannon DD, Burkey JL, Kulanthaivel P.

Drug Metab Dispos. 2006 Feb;34(2):213-24. Epub 2005 Oct 28.

PMID:
16258078
21.

Analytical and biological evaluation of high throughput screen actives using evaporative light scattering, chemiluminescent nitrogen detection, and accurate mass LC-MS-MS.

Peake DA, Duckworth DC, Perun TJ, Scott WL, Kulanthaivel P, Strege MA.

Comb Chem High Throughput Screen. 2005 Sep;8(6):477-87.

PMID:
16178807
22.

(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors.

Wheeler WJ, Clodfelter DK, Collado I, Kulanthaivel P, Pedregal C, Stoddard EA, Wright RA, Schoepp DD.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):349-51.

PMID:
15603952
23.

DOSY of sample-limited mixtures: comparison of cold, nano and conventional probes.

Bradley SA, Paschal J, Kulanthaivel P.

Magn Reson Chem. 2005 Jan;43(1):31-5.

PMID:
15505820
24.

Selective reduction of N-oxides to amines: application to drug metabolism.

Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, Ehlhardt WJ.

Drug Metab Dispos. 2004 Sep;32(9):966-72.

PMID:
15319338
25.

Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening.

Sussman A, Huss K, Chio LC, Heidler S, Shaw M, Ma D, Zhu G, Campbell RM, Park TS, Kulanthaivel P, Scott JE, Carpenter JW, Strege MA, Belvo MD, Swartling JR, Fischl A, Yeh WK, Shih C, Ye XS.

Eukaryot Cell. 2004 Aug;3(4):932-43.

26.

Synthesis and biological activity of some known and putative duloxetine metabolites.

Kuo F, Gillespie TA, Kulanthaivel P, Lantz RJ, Ma TW, Nelson DL, Threlkeld PG, Wheeler WJ, Yi P, Zmijewski M.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6. Erratum in: Bioorg Med Chem Lett. 2004 Oct 18;14(20):5233.

PMID:
15177457
27.

Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I.

Kulanthaivel P, Kreuzman AJ, Strege MA, Belvo MD, Smitka TA, Clemens M, Swartling JR, Minton KL, Zheng F, Angleton EL, Mullen D, Jungheim LN, Klimkowski VJ, Nicas TI, Thompson RC, Peng SB.

J Biol Chem. 2004 Aug 27;279(35):36250-8. Epub 2004 Jun 1.

28.

A natural product ligand of the oxysterol receptor, liver X receptor.

Bramlett KS, Houck KA, Borchert KM, Dowless MS, Kulanthaivel P, Zhang Y, Beyer TP, Schmidt R, Thomas JS, Michael LF, Barr R, Montrose C, Eacho PI, Cao G, Burris TP.

J Pharmacol Exp Ther. 2003 Oct;307(1):291-6. Epub 2003 Jul 31.

PMID:
12893846
29.

Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells.

Reilly CA, Ehlhardt WJ, Jackson DA, Kulanthaivel P, Mutlib AE, Espina RJ, Moody DE, Crouch DJ, Yost GS.

Chem Res Toxicol. 2003 Mar;16(3):336-49.

PMID:
12641434
30.

Biosynthesis of drug glucuronides for use as authentic standards.

Soars MG, Mattiuz EL, Jackson DA, Kulanthaivel P, Ehlhardt WJ, Wrighton SA.

J Pharmacol Toxicol Methods. 2002 May-Jun;47(3):161-8.

PMID:
12628307
31.

Novel naphthoquinones from a Streptomyces sp.

Kulanthaivel P, Perun TJ Jr, Belvo MD, Strobel RJ, Paul DC, Williams DC.

J Antibiot (Tokyo). 1999 Mar;52(3):256-62.

32.

Naturally occurring protein kinase C inhibitors; II. Isolation of oligomeric stilbenes from Caragana sinica.

Kulanthaivel P, Janzen WP, Ballas LM, Jiang JB, Hu CQ, Darges JW, Seldin JC, Cofield DJ, Adams LM.

Planta Med. 1995 Feb;61(1):41-4.

PMID:
7700990
33.

Comparison of balanol from Verticillium balanoides and ophiocordin from Cordyceps ophioglossoides.

Boros C, Hamilton SM, Katz B, Kulanthaivel P.

J Antibiot (Tokyo). 1994 Sep;47(9):1010-6.

34.

Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast.

Ramamoorthy S, Prasad PD, Kulanthaivel P, Leibach FH, Blakely RD, Ganapathy V.

Biochemistry. 1993 Feb 9;32(5):1346-53.

PMID:
8448143
35.

Solubilization and functional reconstitution of the human placental taurine transporter.

Ramamoorthy S, Kulanthaivel P, Leibach FH, Mahesh VB, Ganapathy V.

Biochim Biophys Acta. 1993 Feb 9;1145(2):250-6.

PMID:
8431457
36.

Characterization of an ATP-driven H+ pump in human placental brush-border membrane vesicles.

Simon BJ, Kulanthaivel P, Burckhardt G, Ramamoorthy S, Leibach FH, Ganapathy V.

Biochem J. 1992 Oct 15;287 ( Pt 2):423-30.

38.

Taurine uptake in apical membrane vesicles from the bovine retinal pigment epithelium.

Miyamoto Y, Kulanthaivel P, Leibach FH, Ganapathy V.

Invest Ophthalmol Vis Sci. 1991 Aug;32(9):2542-51.

PMID:
1869409
39.

Inactivation of taurine transporter by calcium in purified human placental brush border membrane vesicles.

Kulanthaivel P, Miyamoto Y, Mahesh VB, Leibach FH, Ganapathy V.

Placenta. 1991 Jul-Aug;12(4):327-40.

PMID:
1946243
40.

Transport of taurine and its regulation by protein kinase C in the JAR human placental choriocarcinoma cell line.

Kulanthaivel P, Cool DR, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapathy V.

Biochem J. 1991 Jul 1;277 ( Pt 1):53-8.

41.

Calcium-induced inhibition of taurine transport in brush-border membrane vesicles from rabbit small intestine.

Miyamoto Y, Kulanthaivel P, Ganapathy V, Whitford GM, Leibach FH.

Biochim Biophys Acta. 1990 Dec 14;1030(2):189-94.

PMID:
2124507
42.

The ATP-binding site of the human placental H+ pump contains essential tyrosyl residues.

Kulanthaivel P, Simon BJ, Burckhardt G, Mahesh VB, Leibach FH, Ganapathy V.

Biochemistry. 1990 Dec 4;29(48):10807-13.

PMID:
2148692
43.

An essential role for vicinal dithiol groups in the catalytic activity of the human placental Na(+)-H+ exchanger.

Kulanthaivel P, Simon BJ, Leibach FH, Mahesh VB, Ganapathy V.

Biochim Biophys Acta. 1990 May 24;1024(2):385-9.

PMID:
2162208
44.

Evidence for tripeptide/H+ co-transport in rabbit renal brush-border membrane vesicles.

Tiruppathi C, Kulanthaivel P, Ganapathy V, Leibach FH.

Biochem J. 1990 May 15;268(1):27-33.

45.

The Na(+)-H+ exchanger of the placental brush-border membrane is pharmacologically distinct from that of the renal brush-border membrane.

Kulanthaivel P, Leibach FH, Mahesh VB, Cragoe EJ Jr, Ganapathy V.

J Biol Chem. 1990 Jan 25;265(3):1249-52.

46.

Tyrosine residues are essential for the activity of the human placental taurine transporter.

Kulanthaivel P, Leibach FH, Mahesh VB, Ganapathy V.

Biochim Biophys Acta. 1989 Oct 16;985(2):139-46.

PMID:
2804101
47.

Inactivation of the human placental serotonin transporter by tyrosyl group-specific reagents.

Ganapathy V, Kulanthaivel P, Tiruppathi C, Mahesh VB, Leibach FH.

J Pharmacol Exp Ther. 1989 Oct;251(1):9-15.

PMID:
2795473
48.

Sesquiterpene Lactones in the Molluscidal Extract of Eremanthus glomerulatus.

Dias Barros DA, Callegari Lopes JL, Vichnewski W, Callegari Lopes JN, Kulanthaivel P, Herz W.

Planta Med. 1985 Feb;51(1):38-9.

PMID:
17340397
49.

Sesquiterpene lactones in the molluscidal extract of Eremanthus glomerulatus.

Dias Barros DA, Callegari Lopes JL, Vichnewski W, Callegari Lopes JN, Kulanthaivel P, Herz W.

Planta Med. 1985 Feb;(1):38-9. No abstract available.

PMID:
4011751
50.

Constituents of Helenium amarum, IV. Desacetyl-1-epiisotenulin.

ElSohly Ma, Kulanthaivel P, Herz W.

J Nat Prod. 1984 May-Jun;47(3):533-5. No abstract available.

PMID:
6548253

Supplemental Content

Loading ...
Support Center